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Medicinal properties of Cannabis sativa L. and its metabolic content 
Cannabis sativa L. has been intensively studied for its metabolic content, with special 
emphasis on the terpenophenolic cannabinoids. Over 500 metabolites [59, 60] have been 
identified from plant extracts including terpenes, sugars, hydrocarbons, steroids, flavonoids, 
nitrogenous compounds, non-cannabinoid phenols and amino acids. In total, around 109 
different cannabinoids have been identified, with tetrahydrocannabinol, cannabidiol, 
cannabigerol and cannabichromene being the most dominant constituents [59, 60]. 
Although the medicinal effect of the cannabinoid content, both pure and mixed isolated, has 
been studied most intensively, also other constituents have been found to be medicinally 
active. In Table 1 a selection of Cannabis sativa L. metabolites is shown including their 
proposed medicinal activity. 
Table 1. Selection of metabolites and their pharmacological activity found within C. sativa sp. 
Group Compound Effect Reference 
Flavonoids Apigenin Anti-inflammatory, anticancer [61] 
 Luteolin Anticancer, immune-modulating [62, 63] 
Methylated 
isoprenoid flavones 
Cannaflavin A Leishmanicidal activity and 
Prostaglandin inhibition 
[64] 
 Cannaflavin B Leishmanicidal activity and 
Prostaglandin inhibition 
[7] 
Terpenes Linalool Anti-anxiety, Analgesic [65, 66] 
 Nerolidol Sedative, anti-malarial [67] 
 Z-β-caryophyllene CB2 agonist [68] 
Terpenophenolic Cannabigerol 2-adrenoceptor agonist [69] 
 Tetrahydrocannabinol Analgesic, Antidepressive  [70] 
 
Legal status within The Netherlands 
There are similar laws existing worldwide regarding C. sativa L. use and cultivation, 
exceptions however, are present. Under certain governmental permits and regular supervision 
for instance, it is allowed to cultivate C. sativa L. for the purpose of fiber production. These 
plants are named hemp and contain usually a low content of cannabinoids. The THCA content 
is not allowed to be higher than 0.2 %, therefore these plants are therefore not attractive for 






sativa (all three chemotypes). Here, The Netherlands has allowed the medicinal use of 
Cannabis sp. since 2003 [14]. Additionally, there are special shops in The Netherlands that 
allow the consumption of Cannabis products for both medicinal and recreational purposes 
[71]. Despite the fact that at this moment, the possession and use is decriminalized, 
cultivation is still an illegal activity. As a consequence the government allows the controlled 
growth of C. sativa L. solely for the purpose of medicinal use. The Ministry of Health, 
Welfare and Sport has created the office of medicinal Cannabis [72], which is now the 
organization responsible for quality control and distribution of the medicinal Cannabis 
products. Besides this ministry is responsible for the supply of permits to scientific activities 
regarding C. sativa cultivation, possession and analysis.  In 2005, this ministry has outsourced 
Cannabis cultivation to the company Bedrocan B.V. that is until now the only company 
allowed to grow C. sativa for legal purposes in The Netherlands [73]. The company has the 
responsibility to standardize the growth and improve the products to the needs of the patients; 




Natural cannabinoids are terpenophenolic compounds that are only biosynthesized in 
Cannabis sativa L., Cannabaceae. For these compounds five different systems of 
nomenclature are available, well described by Shulgin [74] and by ElSohly [59]. Two of these 
systems are mainly employed for the description of tetrahydrocannabinol in publications, 
namely the dibenzopyrane numbering system (1.1 in Figure 1) and the p-cymene-based 
terpene numbering system (1.2 in Figure 1). Because of historical and geographical reasons, 
the standardization is not uniform yet and is the main reason for ongoing confusion in 
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The terpene numbering system, which follows the biochemical nature of compounds, was 
originally developed in Europe [75]. The dibenzopyrane numbering system, which stands in 
agreement with the IUPAC rules, is commonly used in North America. It has the general 
disadvantage that a complete change in numbering occurs after the loss of the terpenoid ring, 
as found in many cannabinoids.  
The chemical name of ∆9-THC according to the dibenzopyrane numbering system is 3-pentyl-
6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6H-dibenzo[b, d]pyran-1-ol as depicted in 1.1 (Figure 
1). Alternatively, the terpene numbering derived name ∆9-tetrahydrocannbinol or simply 
tetrahydrocannabinol is frequently used in the scientific community. When using the short 
name tetrahydrocannabinol or just THC, the stereochemistry of the ∆9-isomer is always 
implied. 
THCA shows no psychotropic effects, but heating (e.g. smoking of Cannabis) leads to its 
decarboxylation providing the major psychoactive constituent of C. sativa; ∆9-THC (2.1 in 
Figure 2). It is a pale yellow resinous oil and sticky at room temperature. It must be noted 
here that hardly any ∆9-THC (decarboxylated THCA) is present within C. sativa and 
tetrahydrocannabinolic acid (THCA) is almost exclusively found. ∆9-THC is lipophilic and 
poorly soluble in water (3 μg mL–1), with a bitter taste but without smell. Furthermore it is 
sensitive to light and air [76]. Some more physical and chemical data on ∆9-THC are listed in 
Table 1. Because of its two chiral centers at C-6a and C-10a, four stereoisomers are known, 
but only (–)-trans-∆9-THC can be found in the Cannabis plant itself [77]. The absolute 
configuration of the natural product was determined as (6aR, 10aR) [78].  
For THC six isomers are possible, whereof the ∆9-isomer and the ∆8-isomer are the most 
important ones. Conformational studies using NMR techniques on ∆9-THC were reported by 
Kriwacki and Makryiannis [79]. The authors discovered that the terpenoid ring and pyrane 
ring of this compound are arranged in a similar way to the half-opened wings of a butterfly. 
An excellent review by Mechoulam et al. [80] has been published providing more information 
on this topic and discussing extensively the stereochemistry of cannabinoids and ∆9-THC, 




























200°C (at 0.02mm Hg) 
 = -150.5° (c = 0.53 in CHCl3 )
a
 
275 nm and 282 nm (ethanol) 
314 (M+); 299; 271; 258; 243; 231 
10.6 
Not stable in acidic solution  




Highly insoluble in water (~ 2.8mg per L at 23°C) 
Highly soluble in methanol, ethanol 
a
 These mass fragments were found by own measurement using GC-MS. 
b
 In the literature values between 6000 and 9 440 000 can be found [81] 
 
Biochemistry and Biosynthesis 
The biosynthesis of the major cannabinoids in C. sativa is located in the glandular trichomes, 
which are located on leaves and flowers. Three resin-producing glandular trichomes are 
known, namely the bulbous glands, the capitate sessile, and the capitate-stalked trichomes. It 
has been reported that the latter contain most cannabinoids [82]. The capitate-stalked 
trichomes become abundant on the bracts when the plant ages and moves into the flowering 
period. The capitate-sessile trichomes show highest densities during vegetative growth [83, 
84]. 
As depicted in Figure 3, in glandular trichomes the cannabinoids are produced in the cells but 
accumulate in the secretory sac of the glandular trichomes, dissolved in the essential oil [83-
87]. Here, ∆9-THC was found to accumulate in the cell wall, the fibrillar matrix and the 
surface features of vesicles in the secretory cavity, the subcutilar wall, and the cuticula of 























































(2.1) R1=H R2=H R3=C5H11
(2.2) R1=COOH R2=H R3=C5H11
(2.3) R1=H R2=COOH R3=C5H11
(2.4) R1=H R2=H R3=C3H7
















Figure 2. Chemical structures of some natural cannabinoids. 
 
As mentioned before, the cannabinoids represent a unique group of secondary metabolites 
called terpenophenolics, meaning that they are composed of a terpenoid and a phenolic 
moiety. The pathway of terpenoid production has already been reviewed exhaustively [88-
91], thus will only be mentioned here shortly. The phenolic unit of cannabinoids is produced 
via the polyketide pathway [92-94]. Both the polyketide and terpenoid pathways merge to the 
cannabinoid pathway and this combination leads to the final biosynthesis of the typical 
cannabinoid skeleton. Here we will discuss different aspects of the cannabinoid pathway 
shared among most cannabinoids, like cannabigerolic acid (CBGA), tetrahydrocannabinolic 






convenience the abbreviations of the acidic form will be used throughout this section because 
they occur as genuine compounds in the biosynthesis. Under plant physiological conditions 
the decarboxylated products will be absent or only present in small amounts. 
 
Figure 3. Representation of mature 
secretory gland originated from C. 
sativa. The separate compartments of 
the glandular trichome are clearly shown 
and the places where THC ac- 
cumulates. Black areas = nuclei, V = 
vacuole, L = vesicle plastid, and ER = 
endoplasmic reticulum.  








The late cannabinoid pathway starts with the alkylation of olivetolic acid (3.2 in Figure 4) as 
polyketide by geranyl diphosphate (3.1 in Figure 4) as the terpenoid unit. Terpenoids can be 
found in all organisms, and in plants two terpenoid pathways are known, the so-called 
mevalonate (MEV) and non-mevalonate (DXP) pathway as described in [89, 96-98]. The 
MEV pathway is located in the cytoplasm of the plant cells [98], whereas the DXP pathway is 
located in the plastids of the plant cells [97] and delivers geranyl diphosphate as one 
important precursor in the biosynthesis. 
Untill recently, the polyketide pathway for olivetolic acid was not yet fully elucidated [108]. 
It was assumed that a polyketide III synthase will either couple three malonyl-CoA units with 
one hexanoyl-CoA unit [93], or catalyze binding of one acetyl-CoA with four malonyl-CoA 
units [94] to biosynthesize olivetolic acid [92-94, 99].  Olivetolic acid as precursor for ∆9-
THC contains a pentyl chain in position C-3 of its phenolic system, but shorter chain lengths 
have also been observed in cannabinoids [100]. These differences in chain length support the 
hypothesis of production by a polyketide, as it is a known feature of these enzymes [101]. It 






polyketide precursors into olivetol [93], however, olivetolic acid was not detected. Similar 
observations were made when feeding isotope-labeled substrates to C. sativa cuttings [102-
104]. Although, Fellermeier et al. [105] showed that only olivetolic acid and not olivetol 
could serve in the enzymatic prenylation with either geranyl diphosphate or neryl 
diphosphate. These main differences seem to derive from studies performed either in planta 
or in vitro [106]. Horper [107] and later Raharjo [93] suggested that the aggregation of the 
enzymes could prevent the decarboxylation of olivetolic acid. This explanation suggests that 
the enzymes are either combined or closely located so that olivetolic acid can be directly 
placed into the site responsible for prenylation. Although this latter hypothesis has not been 
proven yet, recent finding shows that the production of olivetolic acid is dependent on 2 
enzymes. In orde for the polyketide III synthase to produce olivetolic acid it must be co-
assisted by the olivetolic acid cyclase [108] and comes at a cost of olivetol production. The 
intermediate can difuse over short distances, but provides more optimal results when both 
enzymes are in close encounter.  
This finding can also provide new insights for alternative polyketide III enzymes that have the 
ability to produce olivetol-like compounds. In an article by Funa et al., polyketide III 
enzymes were responsible for the formation of phenolic lipid compounds [101], a natural 
product group where olivetol belongs to. This enzyme biosynthesized phenolic lipid’s with 
varying chainlenghts, with the majority containing longer chains. Further studies in 
combination with olivetolic acid cyclase could provide insight into the chain length specificity 
of this specific enzyme and might provide alternative substrates for the prenylase enzyme.  
The precursor of the major cannabinoids is proven to be cannabigerolic acid (CBGA, 3.3 in 
Figure 4) [105, 106]. The formation of this compound is catalyzed by a geranyltransferase 
[94, 105]. This enzyme was purified from crude extracts of young expanding leafs and 
exhibited activity only on olivetolic acid as substrate. Despite the fact that no sequence has 
been published yet, the enzyme was designated geranyldiphosphate:olivetolate 
geranyltransferase (GOT). Recently, the structure and characterization of a geranyltransferase 
named NphB originating from Streptomyces CL109 was reported [109]. The authors claimed 
that the enzyme is able to geranylate both olivetol and olivetolic acid, being thus highly 
similar to the CBGA synthase. This statement however, is based only on the results obtained 
by thin layer chromatography, for further confirmation more precise analytical techniques, 
like LC-MS or NMR, are needed in order to elucidate the structures of the produced products. 
Although more information about GOT than about the polyketide synthase is available (see 

































Figure 4: Biosynthesis of THC and related cannabinoids. (a) GOT; (b) THCs ; (c) CBDs ; (d) CBCs 
 
facilitate further studies. The last enzymatic step of the cannabinoid pathway is the production 
of THCA (3.5 in Figure 4), CBDA (3.4 in Figure 4) or CBCA (3.6 in Figure 4). Three 
different enzymes produce these compounds. The first enzyme produces the major 
psychoactive compound of Cannabis, THCA [21, 38]; the second and third enzymes are 
responsible for the production of CBDA [39] and CBCA [40], respectively. All of these 
enzymes belong to the enzyme group of oxidoreductases [110-113], which means that they 
are able to use an electron donor for the transfer of an electron to an acceptor. From these 
enzymes only the THCA and the CBDA synthase gene sequence have been elucidated. Their 
synthesis products represent also the highest constituents in most C. sativa strains. 
The enzyme responsible for THCA formation is fully characterized and cloned into various 
heterologous organisms where highest activity was mostly detected within the media. 
Bioinformatic analysis of the enzyme indicated a putative signal sequence of 28 amino acids 
(84 bp), suggesting that, under native conditions, the enzyme is transported to a place 
different from where it is produced. Later studies proved that the enzyme is localized in the 






enzyme (purified from C. sativa extracts) did not use any cofactor [113]. Later studies 
indicated however, that a flavin adenine dinucleotide (FAD) cofactor was covalently bound to 
the enzyme. This was confirmed using nucleotide sequence analysis in silico by revealing the 
binding motif for the FAD cofactor. 
CBDA synthase is thought to be an allozyme of THCA synthase, showing 87.9 % identity on 
a nucleotide sequence level. Although the sequence of this gene is known [111, 114], there 
are no reports of its production or characterization. All information gained about the enzyme 
was obtained using protein purified from C. sativa extracts [111]. Although not tested yet, the 
deposited sequence shows the same conserved FAD binding motif as found and proven for 
THCA synthase. Because CBDA synthase also carries the same signal sequence as THCA 
synthase it is suggested that CBDA synthase is localized in the same place as THCA synthase. 
For CBCA synthase hardly any information has been published yet. The enzyme was 
characterized after purification from C. sativa extracts and until this moment no sequence has 
been deposited. Nevertheless, studies indicate that the protein is a homodimeric enzyme of 
136 kDa, thus, two identical domains form the active enzyme. Furthermore, the CBCA 




) than THCA 








, respectively), which is 
probably due to its homodimeric nature [112]. 
Even though a lot of knowledge has been gathered throughout the years using crude extract 
activity studies up till now only one enzyme (THCA synthase) has been reasonably 
characterized. The information gained from the research reported above is already frequently 
used in the breeding and detection of certain chemotypes and will also serve in the future as a 
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Obtained from protein isolation, not heterologous expressed.  
b 
Determined by purified Cannabis extract. 
c 
Determined by recombinant proteins isolates.  
d 
CBDA synthase shown to carry a highly similar N-terminal signal sequence to THCA synthase. It is 
thus suggested that this enzyme is localized at the same position as THCA synthase. Furthermore, the 
precursor CBGA has been shown to be toxic for plant cells and is probably localized in the secretory 
cavity of the glandular trichome. This suggests that CBDA, THCA, CBCA are all localized in the 
storage cavity. 
e 
Activity test with crude extract did not show the need for cofactors; however, from analysis 
performed on THCA synthase, it became clear that FAD is covalently bound to the enzyme. 
Furthermore, analysis of the enzymes THCA and CBDA showed the motif that is conserved for FAD 
binding . 
N.R = not reported 
 
Genetics of Cannabis sativa 
The majority of C. sativa strains exists as a dioeciously (separate sexes) plant species and is 
wind-pollinated. Under normal conditions it is an annual herb, although longer-living C. 
sativa plants have been observed [115, 116]. Some Cannabis strains appear as monoecious 
(containing both male and female parts) cultivars, such as the Ukrainian cultivar USO31 
[117], or as hermaphrodites, but most of these cultivars are not seen in nature. It is estimated 
that only 6 % of the flowering plants are dioecious and they are generally seen as the most 
evolved species within the plant kingdom [118, 119]. Dioecious plants are able to change sex 
during their development. This ability is mostly used as a strategy for survival, however, it 
can be chemically induced.  
The C. sativa genome is normally a diploid, one containing ten chromosome pairs (2n = 20), 






identified for both female (XX) and male plants (XY), the latter was found to be bigger by 47 
Mbp [120, 121]. Additional information was provided recently, by publishing the EST 
(expressed sequence tag) data for the genomes of two Cannabis species [122, 123]. 
C. sativa L. is mostly divided into three major chemotypes. The chemotypes boundaries are 
set by the ratio CBDA: THCA and are calculated as percentage of dry weight. These three 
chemotypes consist of the “fiber”-type (CBDA > THCA), the “intermediate”-type 
(CBDA≈THCA) and the “drug”-type (CBDA < THCA). The chemotypes have been recently 
shown to be dependent either on one locus on the chromosome, or two closely linked loci 
[117],  the former theory is the most likely one [124-126]. The locus is called the B locus and 
until now it was proven to consist of at least two alleles, namely Bt and Bd. There is also an 
indication for a third allele, named B0, which seems to be responsible for a CBGA-dominant 
chemotype [125]. The alleles, Bt and Bd, show co-dominance. The B0 allele is a more 
disputed allele, as it is either recessive or an inactive Bd allele, which can be indicated by 
molecular markers specific for the CBDA gene (Bd allele). The evidence for these alleles was 
gained by breeding with chemotypes and molecular analysis [117]. In crossings made among 
plants of the fiber-type and the drug-type, the intermediate chemotype was obtained as 
offspring. Intercrosses of these F1 plants gave a representative Mendelian ratio (1: 2: 1) of 
chemotypes. This Mendelian ratio suggested one locus to be responsible for the chemotypes. 
Furthermore, Pacifico et al. [117] proved - with the help of multiplex PCR - that a 100 % 
specification of the three accepted chemotypes can be made. This multiplex PCR was 
performed using three primers, where one was designed to anneal to both the THCA synthase 
and the CBDA synthase gene, while the two other primes were specific for either the THCA- 
or CBDA synthase gene. The results showed that the intermediate chemotype was 
heterozygote, containing thus both the CBDA synthase and the THCA synthase genes. The 
drug- and the fiber-types were shown to be homogeneous for either the THCA synthase gene 
or the CBDA synthase gene, respectively.  
Despite the proof of homogeneous distribution of the genes among the different types of 
plants, low levels of THCA for instance can still be detected in the fiber-type group. This may 
be due to the fact that this technique cannot deal yet with polymorphisms present among the 
genes [127]. 
Recently, two more chemotypes have been suggested, one (chemotype 4) with a high content 
of CBGA (B0 allele) and another one (chemotype 5) totally lacking cannabinoids [117]. 







Growing of Cannabis sativa and optimization of THC yield 
Cultivation of Cannabis sativa: 
C. sativa is cultivated for several purposes. Actually, the main legal purpose is the production 
of hemp fibers and pulp. From these materials paper, clothes and ropes are made [128]; 
several Western countries have already legalized the cultivation of C. sativa for these 
purposes. In research, the drug-type of C. sativa is also cultivated, however, only for the 
investigation and determination of forensic studies for chemotype separation. The growth for 
medicinal purposes is hardly performed. In The Netherlands, C. sativa is cultivated for 
medicinal purposes under strictly controlled regulations by the company Bedrocan. In this 
chapter we discuss basic aspects of the cultivation of C. sativa and the optimization of the 
THC content in the plant. 
Optimization of THC yield: 
The optimization of the THC yield is mostly performed through breeding programs. Because 
of the illegality of the plant in most countries, it is either performed in small scale or through 
criminal activities. In the previous section we have already discussed the fact that cannabinoid 
production is mostly genetically determined. This knowledge could thus be used to increase 
the production of certain compounds and decrease the others. The total THC yield is in 
addition, dependent on the amount of accessible precursors and the levels acceptable for the 
plant. Difficulties appear, as in the plant itself, the total content of cannabinoids varies 
enormously. The question remains to what extent THCA production can be increased in the 
plant by breeding programs and/or genetic modifications.  
Genetic modifications seem to be an option for increased yield since the THCA production is 
mainly dependent on genetic factors. Here we could think of increasing glandular trichomes 
densities, increasing precursor production, increasing enzyme activity and knocking out 
enzymes that use the general precursor of THCA (CBGA). Applying some of these 
techniques has already been shown to increase the amount of primary and secondary 
metabolites in microbial organisms [129, 130] and plants [131] . 
Besides breeding programs, the yield of THCA in THCA-dominant plants can be increased by 
environmental influences. In cultivations of the drug-type for example, the male plant is 
excluded from the field inducing more biomass in the female plants due to the lack of 
pollination. Despite the increase in biomass, the exclusion of male plants will not result in a 






Within C. sativa L. there are many phenotypes, e.g. different plant sizes, variations in 
glandular trichomes densities. By combining the phenotypes of various plants with each other, 
a plant could be grown that is large in growth, high in glandular trichomes density, or high in 
THCA content. For instance, through breeding techniques Meijer et al. [125] have already 
created a high CBGA-producing plant, in the drug culture the same has been reached for 
THCA [132]. Preparations were found containing more than 20 % THC, while in the 
literature the reported values lie at 6–10 %. 
Cannabis sativa L. standardization: 
Just like all herbal medicinal preparations, C. sativa work should be standardized if extracts or 
whole plant materials are used for medicinal purposes. Basic requirements include the 
knowledge about all detectable constituents, but also the establishment of a sustainable 
quality control system to achieve the same quality among all batches. For the industrial use of 
Cannabis, standardization is also necessary to equalize the quality of the product. Outdoor 
growth – as usually performed - complicates product standardization due to the environmental 
changes. For this reason, Dutch medicinal C. sativa is grown under strictly controllable 
conditions. At Bedrocan indoor cultivation is performed to maintain high standards of the 
clones regarding quantity and quality. After a strict selective breeding procedure a plant line 
has been established fulfilling all criteria as an herb for medicinal use. 
 
Alternative for controlled production of cannabinoids 
It is clear that production of cannabinoids should be controllable to obtain constant quality of 
certain cannabinoids. With the knowledge of the biosynthetic route it is now possible to 
develop biological production systems as an alternative to chemical synthesis. The major 
advantage of biological systems does not only lie in the production of the structurally right 
natural product, but also in the high yields. Three alternative production strategies are 
pursued. Although two of them are still hypothetical, it should be possible to realize them in 
the near future. 
Cell cultures: 
In literature, several reports can be found on the growth of callus and cell suspension cultures 






cultures, one article [133] showed that cannabinoid secretion could be induced by variations 
in the media.  
Callus and cell suspension are normally induced by standard techniques, the induction of 
callus however, seems to vary among the various C. sativa species [134]. Cell suspensions 
from the callus are maintained in the same media that is used for callus growth, with the 
exception of agar as solidifier. In literature, cell suspensions made from C. sativa callus are 
mostly used for bioconversion studies. There is only one report describing the use of 
cannabinoid precursors for the determination of the induction of cannabinoid production by 
feeding with specific biosynthetic precursors [133]. If production of cannabinoids can be 
achieved in cell cultures, it must still be considered that cannabinoids are toxic to the plant 
cell itself, as these compounds induce the apoptotic response [85]. Thus, at high levels of 
cannabinoid content, techniques have to be developed to extract them from the growth media 
for continuous production. 
 
Transgenic plants: 
At the moment, strategies for the production of transgenic plants are already used for maize, 
tobacco, potato, and rice. The main purpose is to increase their resistance toward diseases 
[136]. In some plants new genes get introduced, leading to the expression of, for example,, 
vitamins [137]. Another purpose of transgenic plants is their use for production of vaccines, 
such as the hepatitis B vaccine in potato plants [138].  
Although the use of transgenic plants is generally not accepted for medicinal herbal 
preparations, transgenic plants could be used to express certain preferable traits. The THCA 
yield could be increased by manipulation of metabolic pathways or by making knockouts of 
biosynthetic genes. With the use of these techniques, the plant could become more resistant 
towards certain parasites and diseases. There is no literature available for the production or 
use of transgenic C. sativa plants. 
 
Heterologous expression of cannabinoid biosynthetic genes: 
Until now there have only been two reports about the heterologous expression of C. sativa 
originating genes. In these reports the yeast Pichia pastoris, hairy root cultures of Nicotiana 
tabacum, BY-2 N. tabacum cell cultures, and insect cells were used to produce THCA 
synthase [110, 139]. Generally, the use of heterologous expression of plant metabolic 
enzymes has been shown to be useful for the production of several compounds [91] indicating 






parameters need to be established because some of the metabolites display toxicity at certain 
concentrations. Here, a possible solution could lie in the constant refreshment of the growth 
medium. Despite the fact that to date, no publications discuss the heterologous production of 
cannabinoids, this strategy could be of high interest for pharmaceutical companies as soon as 
















“If you want to find the secrets of the universe, think in terms of 
energy, frequency and vibration.” 
 
- Nikola Tesla 
